CRDF

Cardiff Oncology Inc

0.9390

Oct 21 • 3:59 PM ET +0.0075 (0.81%)

1.04

Aftermarket • 7:57 PM ET +0.10 (10.92%)

Healthcare Biotechnology USA Micro NASD

Oct 21, 4:40 PMCardiff Oncology announces that the FDA has granted Orphan Drug Designation to its PLK1 inhibitor onvansertib for the treatment of chronic myelomonocytic leukemia (CMML).

Peers: AGEN ELTX ACRV ERAS ONCY OKUR VSTM BBOT KZIA RVMD

| Held by: VTI VXF IWC

Scroll to Statements

Index	-
Market Cap	73.05M
Enterprise Value	38.99M
Income	-40.08M
Sales	0.51M
Book/sh	0.39
Cash/sh	0.44
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	31
IPO	Jul 27, 2004

P/E	-
Forward P/E	-
PEG	-
P/S	143.24
P/B	2.42
P/C	2.12
P/FCF	-
EV/EBITDA	-
EV/Sales	76.46
Quick Ratio	3.30
Current Ratio	3.30
Debt/Eq	0.02
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.59
EPS next Y	-0.61
EPS next Q	-0.14
EPS this Y	16.31%
EPS next Y	-5.38%
EPS next 5Y	-8.14%
EPS past 3/5Y	8.24% 8.71%
Sales past 3/5Y	15.39% 10.13%
EPS Y/Y TTM	32.77%
Sales Y/Y TTM	-6.96%
EPS Q/Q	35.57%
Sales Q/Q	-14.05%
Earnings	Aug 11 AMC
EPS/Sales Surpr.	-17.06% 65.61%

Insider Own	6.17%
Insider Trans	19.29%
Inst Own	21.87%
Inst Trans	-7.03%
ROA	-70.84%
ROE	-94.08%
ROIC	-150.95%
Gross Margin	-75.20%
Oper. Margin	-8320.08%
Profit Margin	-7888.98%
SMA20	-12.62%
SMA50	-13.60%
SMA200	-37.85%
Trades

Shs Outstand	77.80M
Shs Float	73.00M
Short Float	16.54%
Short Ratio	16.12
Short Interest	12.07M
52W High	3.31 -71.63%
52W Low	0.76 24.11%
Volatility	7.78% 6.33%
ATR (14)	0.07
RSI (14)	36.03
Beta	1.53
Rel Volume	0.58
Avg Volume	749.03K
Volume	436,778

Perf Week	-3.53%
Perf Month	-29.40%
Perf Quarter	12.04%
Perf Half Y	-45.72%
Perf YTD	-66.58%
Perf Year	-57.89%
Perf 3Y	-13.85%
Perf 5Y	-84.81%
Perf 10Y	-99.69%
Recom	2.33
Target Price	5.14
Prev Close	0.93
Price	0.94
Change %	0.81%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-15-26	Upgrade	H.C. Wainwright	Neutral → Buy	$9
Aug-12-26	Downgrade	William Blair	Outperform → Mkt Perform
Jun-03-26	Downgrade	Craig Hallum	Buy → Hold	$2
Jun-01-26	Downgrade	TD Cowen	Buy → Hold
Jun-01-26	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-05-26	Initiated	Noble Capital Markets	Outperform	$12
Jul-08-25	Initiated	Ladenburg Thalmann	Buy	$19
Jun-24-25	Initiated	Jefferies	Hold	$3.50
Sep-06-24	Initiated	Craig Hallum	Buy	$8
Jan-05-22	Initiated	William Blair	Outperform
Dec-08-21	Initiated	Robert W. Baird	Outperform	$19
Aug-09-21	Resumed	Maxim Group	Buy	$30 → $20
Oct-22-20	Initiated	H.C. Wainwright	Buy	$27
Oct-08-20	Initiated	Piper Sandler	Overweight	$25

Show Previous Ratings

Oct-21-26 04:05PM	Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia (GlobeNewswire) +10.92%
Sep-14-26 08:30AM	Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement (GlobeNewswire) +8.26%
Sep-02-26 07:00AM	Cardiff Oncology to Participate in September 2026 Conferences (GlobeNewswire)
Aug-11-26 04:46PM	Cardiff Oncology: Q2 Earnings Snapshot (Associated Press) -5.67%
04:10PM	Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update (GlobeNewswire)
10:54AM	Loading…
Jul-15-26 10:54AM	Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital (InvestorsHub) -32.11%
08:00AM	Cardiff Oncology Announces $10 Million Registered Direct Offering (GlobeNewswire)
Jun-02-26 09:06AM	Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting (GlobeNewswire)
Jun-01-26 04:01PM	Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -22.11%
May-21-26 05:00PM	Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC (GlobeNewswire)
May-14-26 04:22PM	Cardiff Oncology: Q1 Earnings Snapshot (Associated Press)
04:10PM	Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update (GlobeNewswire)
Apr-28-26 04:01PM	Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-27-26 07:00AM	Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent Activity (GlobeNewswire)
Apr-21-26 10:00AM	Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026 (GlobeNewswire) -7.30%
04:01PM	Loading…
Apr-17-26 04:01PM	Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting (GlobeNewswire) +6.51%
Apr-09-26 04:01PM	Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth (GlobeNewswire) +7.05% -5.39%
Mar-27-26 08:05AM	These 16 stocks are a short seller's dream - likely losers no matter what the market does (MarketWatch) -7.19%
Mar-20-26 07:00AM	Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer (GlobeNewswire)
Mar-19-26 07:00AM	Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting (GlobeNewswire)
Feb-26-26 04:01PM	Cardiff Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
04:32AM	Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC (MarketBeat)
Feb-24-26 05:26PM	Cardiff Oncology: Q4 Earnings Snapshot (Associated Press Finance) +8.97% +12.35%
04:30PM	Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update (GlobeNewswire)
Feb-19-26 07:00AM	Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-28-26 06:23AM	Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus (Benzinga) -19.00%
Jan-27-26 10:54AM	Cardiff Oncology Taps Interim CEO, Picks 30mg Onvansertib Regimen for 2026 Registrational mCRC Study (MarketBeat) -31.97%
07:05AM	Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC (GlobeNewswire)
07:00AM	Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development (GlobeNewswire)
Dec-08-25 04:05PM	Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 (GlobeNewswire) +10.90%
07:00AM	Loading…
07:00AM	Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference (GlobeNewswire)
Nov-24-25 07:00AM	Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-06-25 04:33PM	Cardiff Oncology: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update (GlobeNewswire)
Nov-04-25 04:01PM	Cardiff Oncology to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-02-25 04:05PM	Cardiff Oncology to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-28-25 04:05PM	Cardiff Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Jul-29-25 05:25PM	Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -11.26% -24.77%
04:23PM	Cardiff Oncology: Q2 Earnings Snapshot (Associated Press Finance)
04:07PM	Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004) (GlobeNewswire)
04:05PM	Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update (GlobeNewswire)
Jun-19-25 09:25AM	Cardiff Oncology to share CRDF-004 trial data on July 29 (TipRanks)
09:25AM	Cardiff selloff brings attractive entry point, says H.C. Wainwright (TipRanks)
Jun-17-25 04:05PM	Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC (GlobeNewswire) -18.38%
Jun-02-25 04:05PM	Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 (GlobeNewswire)
May-14-25 12:00PM	Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know (Zacks)
May-08-25 05:25PM	Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.62%
04:05PM	Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update (GlobeNewswire)
May-02-25 03:35AM	Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon (Seeking Alpha)
Apr-28-25 10:00AM	ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-24-25 10:01AM	Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-23-25 04:05PM	Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naive Patients (GlobeNewswire)
04:05PM	Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Na ve Patients (GlobeNewswire)
Apr-15-25 04:10PM	Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.38%
04:05PM	Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer (GlobeNewswire)
Mar-26-25 03:57PM	Is Cardiff Oncology, Inc. (CRDF) The Hot Biotech Stock Under $5? (InsiderMonkey) -6.84%
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
Feb-27-25 04:05PM	Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update (GlobeNewswire) -8.97%
Feb-26-25 08:12AM	Cardiff Oncology Inc (CRDF) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com) +5.44%
Feb-24-25 04:05PM	Cardiff Oncology to Present at Upcoming Investor Conferences (GlobeNewswire) -7.24%
Feb-20-25 04:05PM	Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update (GlobeNewswire)
Dec-26-24 09:00AM	Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook (GlobeNewswire) +10.71%
Dec-20-24 12:52PM	Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses (PR Newswire) -5.12%
Dec-18-24 11:12AM	Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments (PR Newswire) -16.07%
Dec-14-24 06:50AM	Cardiff Oncology price target raised to $10 from $7 at Piper Sandler (TipRanks)
Dec-11-24 07:19AM	Cardiff Oncology Reports Promising Phase 2 Trial Results (TipRanks)
Dec-10-24 07:20AM	Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering (GlobeNewswire) +54.92%
06:00AM	Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial (GlobeNewswire)
Nov-19-24 08:00AM	Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC (GlobeNewswire)
Nov-07-24 04:05PM	Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update (GlobeNewswire) +7.35% -24.69%
Oct-30-24 04:30PM	Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC (GlobeNewswire)
Aug-08-24 04:05PM	Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update (GlobeNewswire) +11.74%
Aug-01-24 04:05PM	Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update (GlobeNewswire)
May-29-24 04:05PM	Cardiff Oncology to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-13-24 04:05PM	Cardiff Oncology to Present at Upcoming Investor Conferences in May (GlobeNewswire)
May-09-24 12:15PM	Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036 (PR Newswire) +5.63%
May-07-24 06:00AM	The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028 (InvestorPlace)
May-02-24 09:54PM	CRDF Stock Earnings: Cardiff Oncology Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.91% -21.43%
05:45PM	Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update (GlobeNewswire)
Apr-25-24 04:05PM	Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update (GlobeNewswire)
Apr-08-24 04:05PM	Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study (GlobeNewswire)
Apr-01-24 08:50AM	Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) +7.30%
Mar-21-24 07:55AM	Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why (Zacks)
Mar-14-24 08:50AM	Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going (Zacks)
08:08AM	Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last? (Zacks)
Mar-06-24 04:05PM	Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024 (GlobeNewswire) +6.58% -9.77%
12:00PM	What Makes Cardiff Oncology (CRDF) a Strong Momentum Stock: Buy Now? (Zacks)
Mar-01-24 10:12AM	Cardiff Oncology Inc (CRDF) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com) +64.87%
Feb-29-24 07:40PM	Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update (GlobeNewswire)
04:06PM	Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC (GlobeNewswire)
04:05PM	Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004) (GlobeNewswire)
Feb-26-24 08:00AM	Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-22-24 08:00AM	Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update (GlobeNewswire)
Jan-17-24 10:30AM	Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research (PR Newswire) -9.82%
Nov-20-23 04:05PM	Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference (PR Newswire)
Nov-02-23 04:05PM	Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update (PR Newswire) +8.57%
Oct-26-23 04:05PM	Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update (PR Newswire)
Oct-23-23 08:45AM	Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing (PR Newswire) -10.27%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PACE GARY W	Director	Jul 14 '26	Buy	1.46	687,285	1,000,000	2,043,661	Jul 16 04:03 PM
Mohindru Mani	Chief Executive Officer	Jul 14 '26	Buy	1.46	34,364	50,000	59,067	Jul 16 04:01 PM
Mohindru Mani	Chief Executive Officer	Jun 18 '26	Buy	1.21	24,703	29,891	24,703	Jun 22 09:00 AM
PACE GARY W	Director	Jun 18 '26	Buy	1.22	30,000	36,600	1,356,376	Jun 22 09:00 AM

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The firm is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

PresidentDr. Mani Mohindru Ph.D.

M.D.Dr. Roger Sidhu FRCPC

M.B.A.Mr. Joshua Muntner BFA

M.D.Dr. Ajay Aggarwal M.B.A.

Chief Accounting OfficerMs. Brigitte Lindsay

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRDF

Cardiff Oncology Inc

Upgrade your Finviz experience